Chagas 112- 2-Iminothiazolidin-4-ones arrest *Trypanosoma cruzi* growth and impair trypomastigote development in macrophages

Meira, C. S.1, Guimarães, E. T.1, Moreira, D. R. M.3, Leite, A. C. L.3, Pereira, V. R. A.4, Melo, C. M. L.4, Neves, J. K. A. L.4, Soares, M. B. P.1,2

¹Gonçalo Moniz Research Center, Oswaldo Cruz Foundation, Salvador, BA, Brazil, ²Center of Biotechnology and Cell Therapy, Hospital São Rafael, Salvador, BA, Brazil, ₃Department of Pharmaceutical Sciences, Federal University of Pernambuco, Recife, PE, Brazil, ₄Department of Immunology, Aggeu Magalhaes Research Center, Oswaldo Cruz Foundation, Recife, PE, Brazil

Chagas disease, caused by the flagellate protozoan Trypanosoma cruzi, affects about 18 million people in the Americas. Current chemotherapy of Chagas disease is based on benznidazole, which is toxic and has limited efficacy. Therefore, new chemotherapeutic agents need to be developed. In this work, we describe the identification of eight Trypanosoma cruzi inhibitors through a combination of thiazoles and hydrazones chemistry. The trypanocidal effect against T. cruzi was first evaluated by light microscopy through the determination of IC50 values for the replicative form epimastigote and bloodstream trypomastigotes of Y strain. Cytotoxicity was determined by incorporation of [3H]- thymidine by splenocytes obtained from normal mice. The trypanocidal activity of the iminothiazolidin-4-ones was tested in a model of infection in vitro of macrophage cultures. All compounds showed activity for the replicative form epimastigote and the infective form trypomastigote, showing IC50 values ranging from 0.5 to 51.5 μM and 1.2 to 48.2 μM, respectively. In terms of cytotoxicity, compounds TS-40 and TS-59 showed the best profiles. The compounds had IC50 values of 9 µM and 1.2 µM, respectively, for trypomastigotes and IC₅₀ values of 5.1 and 0.5 μM, respectively, for epimastigotes. All the values smaller than the IC₅₀ of the standard drug (benznidazole IC₅₀ = $11.2 \mu M$ for trypomastigotes and $7.5 \mu M$ for epimastigotes). In splenocyte cultures, all the compounds showed no or moderate cytotoxicity, demonstrating a selective toxicity of these compounds, especially compound TS-59, which is over 180 times more cytotoxic to trypomastigote than for mammalian cells. In the model of macrophage infection with Trypanosoma cruzi, all the iminothiazolidin-4-ones were able to reduce the percentage of macrophages infected and the relative number of amastigotes per cell. The compounds TS-40 and TS-59 showed the best activity. The IC₅₀ of these compounds were 10.11 \pm 0.09 μ M for TS-40, and of 5.20 \pm 0.54 μ M for TS-59, while benznidazole had an IC50 of 13.99±0.39 μM. Our results with iminothiazolidin-4-ones TS-40 and TS-59 argue for the evaluation of these compounds in the in vivo infection model in mice. E-mail: calcio0303@hotmail.com